SCM
TVTX icon

Superstring Capital Management’s Travere Therapeutics TVTX Stock Holding History

Superstring Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-102,754
Closed -$3.05M – 41
2026
Q1 		$3.05M Buy
102,754
+64,732
+170% +$1.94M 2.18% 19
2025
Q4 		$1.45M Sell
38,022
-15,605
-29% -$507K 0.78% 31
2025
Q3 		$1.28M Sell
53,627
-222,847
-81% -$4.19M 1.26% 28
2025
Q2 		$4.09M Buy
276,474
+38,987
+16% +$646K 4.84% 10
2025
Q1 		$4.26M Buy
+237,487
New +$4.82M 5.06% 9

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Superstring Capital Management's TVTX Position: Q2 2026 in Review

Superstring Capital Management sold out of Travere Therapeutics (TVTX) in Q2 2026, closing a stake of 102,754 shares — an estimated $3.05M sold.

Superstring Capital Management first reported a position in TVTX in Q1 2025 and held it in 5 quarters. The position peaked at $4.26M in Q1 2025. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Superstring Capital Management reported no remaining Travere Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Superstring Capital Management sold 102,754 Travere Therapeutics shares in Q2 2026, an estimated $3.05M.
  • Superstring Capital Management first reported a position in Travere Therapeutics in Q1 2025 and held it in 5 quarters.
  • Superstring Capital Management's Travere Therapeutics position peaked at $4.26M in Q1 2025.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Superstring Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.